Literature DB >> 10368637

Doxorubicin-induced cell death in highly invasive human gliomas.

A C Stan1, S Casares, D Radu, G F Walter, T D Brumeanu.   

Abstract

Glioblastoma is the most invasive form of primary brain tumors, and is often refractory to chemotherapy. Herein, we provide evidence that two highly invasive human glioma cell lines U-87 MG and U-373 MG, entered apoptosis after 48 hours following 24 h growth arrest induced by Doxorubicin (10 micrograms/2 x 10(5) cells/ml). Apoptosis depended solely on the level of intracellular drug accumulation, and it was not related to a functional p53 tumor suppressor factor. The multidrug resistance gene 1 (mdr-1) encoded P-glycoprotein (P-gp) was weakly expressed in these cells upon exposure to Doxorubicin, and exerted no influence on the extent of cellular drug efflux. Drug efflux occurred only in U-373 MG glioma cells subsequent to physical damage of the membrane upon exposure to Doxorubicin. Pretreatment of tumor cells with 10 micrograms/ml Doxorubicin precluded tumor formation on the chorioallantoic membrane (CAM) of embryonated hen eggs. Single-dose application of 0.4 microgram Doxorubicin on CAM/U-87 MG and CAM/U-373 MG tumor transplants inhibited tumor invasion in CAM tissue by 40 to 50%. These data suggest that highly invasive glioblastomas can be driven to apoptosis following growth arrest induced by Doxorubicin, providing that intracellular drug accumulation suffices cytotoxic levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10368637

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Nathan McDannold
Journal:  J Control Release       Date:  2015-02-24       Impact factor: 9.776

2.  Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma.

Authors:  Lisa H Treat; Nathan McDannold; Yongzhi Zhang; Natalia Vykhodtseva; Kullervo Hynynen
Journal:  Ultrasound Med Biol       Date:  2012-07-19       Impact factor: 2.998

3.  The kinetics of blood brain barrier permeability and targeted doxorubicin delivery into brain induced by focused ultrasound.

Authors:  Juyoung Park; Yongzhi Zhang; Natalia Vykhodtseva; Ferenc A Jolesz; Nathan J McDannold
Journal:  J Control Release       Date:  2012-06-15       Impact factor: 9.776

4.  Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate.

Authors:  Tânia Capelôa; Francisco Caramelo; Carlos Fontes-Ribeiro; Célia Gomes; Ana P Silva
Journal:  Neurotox Res       Date:  2014-03-21       Impact factor: 3.911

5.  Chondroitin sulphate-modified neuropilin 1 is expressed in human tumour cells and modulates 3D invasion in the U87MG human glioblastoma cell line through a p130Cas-mediated pathway.

Authors:  Paul Frankel; Caroline Pellet-Many; Pauliina Lehtolainen; Giovanna M D'Abaco; Michelle L Tickner; Lili Cheng; Ian C Zachary
Journal:  EMBO Rep       Date:  2008-08-15       Impact factor: 8.807

6.  Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.

Authors:  Wenjia Guo; Hailong Tian; Xiaogang Dong; Jinping Bai; Xinling Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

7.  Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model.

Authors:  Muna Aryal; Natalia Vykhodtseva; Yong-Zhi Zhang; Juyoung Park; Nathan McDannold
Journal:  J Control Release       Date:  2013-04-18       Impact factor: 9.776

8.  Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes.

Authors:  Arabinda Das; Naren L Banik; Swapan K Ray
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

9.  Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles.

Authors:  Yuebin Zhang; Jia Yu; Lifeng Zhang; Jiabin Cai; Doute Cai; Chengjie Lv
Journal:  Tumour Biol       Date:  2015-09-24

10.  Reinduction of bevacizumab in combination with pegylated liposomal Doxorubicin in a patient with recurrent glioblastoma multiforme who progressed on bevacizumab/irinotecan.

Authors:  Mohammed Almubarak; Michael Newton; Ramin Altaha
Journal:  J Oncol       Date:  2008-09-02       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.